Risperdal and Tracleer drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Risperdal (risperidone) and Tracleer (bosentan). Common drug interactions include dyspnoea among females and alanine aminotransferase increased among males.

The phase IV clinical study analyzes what interactions people have when they take Risperdal and Tracleer. It is created by eHealthMe based on reports of 30 people who take the same drugs from the FDA, and is updated regularly.

What is Risperdal?

Risperdal has active ingredients of risperidone. It is often used in bipolar disorder. eHealthMe is studying from 127,729 Risperdal users. Check the latest studies of Risperdal.

What is Tracleer?

Tracleer has active ingredients of bosentan. It is often used in primary pulmonary hypertension. eHealthMe is studying from 55,125 Tracleer users. Check the latest studies of Tracleer.



On Jul, 11, 2026

30 people who take Risperdal and Tracleer together, and have interactions are studied.

Risperdal and Tracleer drug interactions.

What are the common drug interactions of Risperdal and Tracleer, by gender? *:

female:

  1. Dyspnoea (difficult or laboured respiration)
  2. Hospitalisation
  3. Fluid retention (an abnormal accumulation of fluid in the blood)
  4. Oedema peripheral (superficial swelling)
  5. Pulmonary hypertension (increase in blood pressure in the lung artery)
  6. Fall
  7. Pneumonia
  8. Skin ulcer
  9. Subdural haematoma (blood collects between the skull and the surface of the brain)
  10. Acute respiratory failure

male:

  1. Alanine aminotransferase increased
  2. Aspartate aminotransferase increased
  3. Headache (pain in head)
  4. Intercostal neuralgia (inflammation of the intercostal nerves)
  5. Movement disorder (neurological syndromes where they may be excess of movement or a paucity of movement that is not connected to weakness)
  6. Pain in jaw
  7. Swelling face
  8. Swollen tongue (swelling of tongue)
  9. Vitreous detachment (a condition of the eye in which the vitreous humour separates from the retina)
  10. Vitreous floaters (spots before the eyes)

What are the common drug interactions of Risperdal and Tracleer, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

  1. Generalised oedema (swelling all over the body)
  2. Oedema (fluid collection in tissue)
  3. Pulmonary thrombosis (scarring in the lungs)

10-19:

n/a

20-29:

  1. Alanine aminotransferase increased
  2. Aspartate aminotransferase increased
  3. Blood alkaline phosphatase increased
  4. Blood bilirubin increased
  5. Pulmonary haemorrhage (acute bleeding from the lung)

30-39:

  1. Dysphonia (speech disorder attributable to a disorder of phonation)
  2. Laryngeal pain
  3. Oedema peripheral (superficial swelling)
  4. Sinusitis (inflammation of sinus)
  5. Alanine aminotransferase increased
  6. Aspartate aminotransferase increased
  7. Blood lactate dehydrogenase increased
  8. Diarrhoea
  9. Dystonia (abnormal muscle tone)
  10. Headache (pain in head)

40-49:

  1. Pulmonary hypertension (increase in blood pressure in the lung artery)

50-59:

  1. Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
  2. Pain in extremity

60+:

  1. Alanine aminotransferase increased
  2. Aspartate aminotransferase increased
  3. Anaemia (lack of blood)
  4. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  5. Cardiac arrest
  6. Cardiac failure chronic
  7. Chronic kidney disease
  8. Death
  9. Diarrhoea
  10. Erysipelas (bacterial skin infection)

What are the existing conditions these people have? *

  1. Pulmonary Hypertension (increase in blood pressure in the lung artery): 14 people, 46.67%
  2. Pulmonary Embolism (blockage of the main artery of the lung): 3 people, 10.00%
  3. Cardiac Failure: 3 people, 10.00%
  4. Schizophrenia (a mental disorder characterized by a breakdown of thought processes): 2 people, 6.67%
  5. Indigestion: 2 people, 6.67%
  6. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 6.67%
  7. Depression: 2 people, 6.67%
  8. Delirium (wild excitement): 2 people, 6.67%
  9. Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 2 people, 6.67%
  10. Agitation (state of anxiety or nervous excitement): 2 people, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Risperdal and Tracleer?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Risperdal and Tracleer:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Risperdal:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Tracleer:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Risperdal and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Tracleer and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on risperidone and bosentan (the active ingredients of Risperdal and Tracleer, respectively), and Risperdal and Tracleer (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: